Literature DB >> 25482146

Financing cures in the United States.

Anirban Basu1.   

Abstract

True cures in health care are rare but likely not for long. The high price tag that accompanies a cure along with its rapid uptake create challenges in the financing of cures by public and private payers. In the US, the disaggregated nature of health insurance system adds to this challenge as patients frequently churn across multiple health plans. This creates a 'free-rider' problem, where no one health plan has the incentive to invest in cure since the returns will be scattered over many health plans. Here, a new health currency is proposed as a generalized version of a social impact bond that has the potential to solve this free-rider problem, as it can be traded not only between public and private payers but also within the private sector. An ensuing debate as to whether and how to develop such a currency can serve the US health care system well.

Entities:  

Keywords:  credit markets; cures; financing; public good; sovaldi

Mesh:

Year:  2014        PMID: 25482146     DOI: 10.1586/14737167.2015.990887

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  5 in total

1.  Avoiding the Tragedy of the Commons in Health Care: Policy Options for Covering High-Cost Cures.

Authors:  Soeren Mattke; Hangsheng Liu; Emily Hoch; Andrew W Mulcahy
Journal:  Rand Health Q       Date:  2017-01-13

Review 2.  Value and affordability of CAR T-cell therapy in the United States.

Authors:  Salvatore Fiorenza; David S Ritchie; Scott D Ramsey; Cameron J Turtle; Joshua A Roth
Journal:  Bone Marrow Transplant       Date:  2020-05-30       Impact factor: 5.483

Review 3.  Clinical impact of alcohol-related cirrhosis in the next decade: estimates based on current epidemiological trends in the United States.

Authors:  John Guirguis; Jagpreet Chhatwal; Jaividhya Dasarathy; John Rivas; David McMichael; Laura E Nagy; Arthur J McCullough; Srinivasan Dasarathy
Journal:  Alcohol Clin Exp Res       Date:  2015-10-25       Impact factor: 3.455

4.  Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia.

Authors:  Melanie D Whittington; R Brett McQueen; Daniel A Ollendorf; Varun M Kumar; Richard H Chapman; Jeffrey A Tice; Steven D Pearson; Jonathan D Campbell
Journal:  JAMA Pediatr       Date:  2018-12-01       Impact factor: 16.193

5.  Assessing potential cures: are there distinctive elements of value beyond health gain?

Authors:  Saskia Hendriks; Steven D Pearson
Journal:  J Comp Eff Res       Date:  2021-03-05       Impact factor: 1.744

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.